Unleashing global market access success

Life sciences companies face many complexities when venturing into new markets overseas, including expansion within the E.U. and the U.K. From determining the required level of evidence to securing payer and provider coverage, to effectively conveying the value of products, devices, or therapeutics, entering new markets demands careful planning and execution.

Join Baker Tilly for an informative webinar where our team will discuss how entering into a new market and diversifying your portfolio can position your life sciences company for long-term success.

Our team of specialists will explore the risks involved and strategies to overcome those challenges to achieve market access success in foreign markets, emphasizing the importance of having a solid evidence-generation strategy. Additionally, we will delve into how leveraging data and understanding the approval process by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) can contribute to your company streamlining commercial success in the U.S. and abroad, including the perspective from the U.K.’s National Institute for Health and Care Education (NICE).

 Who should attend

• C-Suite executives as well as professionals involved in market access, medical affairs, health economics and outcomes research (HEOR), compliance and operations of life sciences companies that operate in multiple countries or are looking to expand into additional markets in the coming years.

 Moderator

• Arun Parekkat, MBA, MS, Managing Director, Baker Tilly

Panelists

• David Gregory, MPA, FACHE, Principal, Baker Tilly
• Grace Macalino, PhD, MPH, Director, Baker Tilly
• Sheela Upadhyaya, Consultant in Rare Diseases Market Access & Evidence Strategies. Chair, International Society for Patient Outcomes Research (ISPOR) Rare Disease Special Interest Group (SIG) and former NICE advisor

Learning objectives

• Define the risks and challenges involved in entering new foreign markets and diversifying a life sciences company’s portfolio
• Explore strategies to achieve market access success within new markets, with an emphasis on developing a solid evidence-generation strategy
• Demonstrate how leveraging data and understanding the approval processes of regulatory agencies like the FDA, EMA, and NICE can contribute to streamlining commercial success for life sciences companies